Novartis takes Gilenya fight to Supreme Court as generic competition looms
Novartis stands to lose more than a quarter billion dollars in sales this year if Gilenya generics are allowed to market. So it’s taking the fight all the way to the Supreme Court.
The Swiss pharma giant announced on Wednesday that a US federal appeals court has refused to rehear its Gilenya patent case against private Chinese biotech HEC Pharm. Next up? Novartis plans on petitioning the Supreme Court to uphold the validity of its patent No. 9,187,405, referred to in court documents as the ‘405 patent, covering a 0.5 mg dosing regimen of the multiple sclerosis drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.